No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 4.7x · 10Y median 3.6x · 62nd percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 21
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-02-23.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T22:24:15.007Z. Latest historical point 2026-05-04. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for GeneDx Holdings Corp. (WGS) stock was $71.52 as of Oct 6, 2026, 4:00 PM EDT, down 6.23% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -35.4% · 3-year avg +184.5%/yr · 5-year avg -19.7%/yr
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services.
Medical - Diagnostics & Research · Stamford, CT
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Next Earnings Date
Oct 27, 2026
21 days away
EPS Estimate
0.07
Revenue Est.
$122.93M
Last Quarter Results
EPS
$0.01
vs Estimate
$-0.19
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1WGS | $2.13B | $71.52 | -6.23% | -35.37% | -19.67% | N/A | N/A |
| 2ADUS | $2.11B | $113.16 | +0.16% | +0.25% | +8.33% | +15.62% | vs WGS |
| 3VERA | $2.11B | $29.42 | -1.37% | -1.02% | +14.09% | N/A | vs WGS |
| 4SLS | $2.11B | $11.34 | -2.49% | +516.69% | +6.20% | -49.07% | vs WGS |
| 5MRVI | $2.17B | $7.85 | -7.86% | +174.40% | -27.63% | N/A | vs WGS |
| 6PHVS | $2.17B | $31.12 | +2.07% | +30.19% | +11.45% | N/A | vs WGS |
forward FY estimate
N/A
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
$114.44M
vs Estimate
$111.01M
Consensus Rating
Based on 8 analysts
Average Price Target
$93.50
+30.7% upside
Low
$83.00
Current
$71.52
High
$103.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $0.07 | $0.07 | $0.07 | 4 |
| Quarter ending Dec 2026 | $0.29 | $0.29 | $0.29 | 4 |
| Quarter ending Mar 2027 | $0.04 | $0.04 | $0.04 | 1 |
| Quarter ending Jun 2027 | $0.23 | $0.23 | $0.23 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $0.10 | $0.10 | $0.10 | 4 |
| FY 2027 | $1.15 | $1.20 | $1.25 | 4 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $121.43M | $122.93M | $123.61M | 4 |
| Quarter ending Dec 2026 | $140.90M | $142.64M | $143.43M | 4 |
| Quarter ending Mar 2027 | $128.66M | $130.25M | $130.97M | 2 |
| Quarter ending Jun 2027 | $141.41M | $143.16M | $143.95M | 2 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $467.54M | $482.26M | $497.80M | 6 |
| FY 2027 | $580.64M | $598.92M | $618.22M | 5 |
